Lumos Diagnostics Holdings Limited (LDXHF)

Market Cap	15.06M
Revenue (ttm)	14.67M
Net Income (ttm)	-4.98M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	41,837
Open	0.0300
Previous Close	0.0290
Day's Range	0.0260 - 0.0300
52-Week Range	0.0100 - 0.3337
Beta	0.70
RSI	58.73
Earnings Date	May 28, 2025

About LDXHF

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers. The company was incorporated in 2018 and is based in Carl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: LDXHF

Financial Performance

In 2024, LDXHF's revenue was $11.13 million, an increase of 5.66% compared to the previous year's $10.54 million. Losses were -$8.59 million, -4.22% less than in 2023.